The lack of short-term cardiovascular benefit observed when therapies to improve glycaemic control are used in patients with diabetes mellitus has drawn attention to the need to limit potential risks of treatment, especially those related to hypoglycaemia. A recent report considers HbA1c levels <7% in older people a sign of overtreatment, but other findings suggest additional ways to identify and control risk.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Turnbull, F. M. et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52, 2288–2298 (2009).
Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545–2559 (2008).
Lipska, K. J. et al. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern. Med. http://dx.doi.org/10.1001/jamainternmed.2014.7345.
Zoungas, S. et al. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med. 363, 1410–1418 (2010).
Bonds, D. E. et al. The association between symptomatic severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiologic analysis of the ACCORD study. BMJ 340, b4909 (2010).
Mellbin, L. G. et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur. Heart J. 34, 3137–3144 (2013).
Riddle, M. C. & Karl, D. M. Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care 35, 2100–2107 (2012).
Calles-Escandon, J. et al. Effect of intensive compared with standard glycemic treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 33, 721–727 (2010).
Riddle, M. C. et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4–year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33, 983–990 (2010).
Miller, M. E. et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial. Diabetes Care 37, 634–643 (2014).
Acknowledgements
M.C.R. acknowledges support from the Rose Hastings and Russell Standley memorial trusts.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.C.R. has received research grants from AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi, has acted as a consultant for Biodel, Elcelyx, Sanofi and Veleritas, and has received honoraria from Sanofi.
Rights and permissions
About this article
Cite this article
Riddle, M. Controlling glucose levels in elderly people—benefits versus risks. Nat Rev Endocrinol 11, 257–258 (2015). https://doi.org/10.1038/nrendo.2015.23
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2015.23
